Key facts
- This page summarizes Patrick J. Mahaffy's Form 4 filing for Clovis Oncology, Inc..
- 3 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 03 Mar 2022, 15:15.
Patrick J. Mahaffy - 01 Mar 2022 Form 4 Insider Report for Clovis Oncology, Inc.
- Reporting relationship
- President and Chief Executive Officer, Director
- Issuer ticker
- N/A
- Reported as of
- 01 Mar 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Mar 2022, 15:15:52 UTC
- Prior SEC filing
- 19 Nov 2021
- Next SEC filing
- 08 Sep 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Patrick Mahaffy
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Patrick J. Mahaffy filed Form 4 for Clovis Oncology, Inc. on 03 Mar 2022.
Change
- Previous filing in this sequence was filed on 19 Nov 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLVS
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +220,000
- Change %
- Price
- $0.000000
- Shares after
- 220,000
- Date
- 01 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 220,000
- Exercise price
- $1.95
- Footnotes
- F1
CLVS
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +80,000
- Change %
- Price
- $0.000000
- Shares after
- 80,000
- Date
- 01 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 80,000
- Exercise price
- $1.95
- Footnotes
- F2
CLVS
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +80,000
- Change %
- Price
- $0.000000
- Shares after
- 80,000
- Date
- 01 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 80,000
- Exercise price
- $1.95
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The option shall vest as to 25% of the shares on March 1, 2023, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date.
Footnote F2
The option shall vest in the event Product Revenues for the Company's fiscal year ending December 31, 2022 meet or exceed its corresponding budgeted amount in the Company's budget as approved by the Board on December 2, 2021.
Footnote F3
The option shall vest on December 31, 2022 if as of such date the Company has sufficient cash and cash equivalents or available sources of borrowings to fund the Company's operating plan, as approved by the Board as of such date, into 2024.
SEC remarks
President and Chief Executive Officer